SBFM
SUNSHINE BIOPHARMA INC.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $0.00 | $0.51 | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments | Q4 2025 | Q1 2026 | → $1.16 | -29% |
| Renaissance Technologies | Q3 2025 | Q1 2026 | → $1.18 | -21% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Sunshine Biopharma Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Apr 14, 2026 — the most recent Form 4 on file — not from today.
- Form 40001683168-26-002922Apr 14, 2026
- Form 40001683168-24-001322Mar 5, 2024
- Form 40001683168-24-000879Feb 12, 2024
- Form 40001683168-22-008144Dec 2, 2022
- Form 40001683168-22-004178Jun 6, 2022
- Form 40001683168-22-001185Feb 22, 2022
- Form 40001128732-21-000003Feb 16, 2021
- Form 40001128732-21-000002Feb 16, 2021
- Form 40001128732-21-000001Feb 16, 2021
- Form 40001128732-20-000005Jul 15, 2020
- Form 40001128732-20-000004Jul 13, 2020
- Form 40001128732-20-000003Jul 10, 2020
- Form 40001128732-20-000002Jun 25, 2020
- Form 40001128732-19-000032Oct 7, 2019
- Form 4/Aamend0001128732-19-000031Oct 7, 2019
Fundamentals
XBRL · SUNSHINE BIOPHARMA INC.Annual figures sourced directly from SUNSHINE BIOPHARMA INC.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Sunshine Biopharma Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KCURRENT REPORTMay 29, 2026
- 8-KCURRENT REPORTMay 19, 2026
- 10-QFORM 10-Q FOR MAR 2026May 13, 2026
- S-1FORM S-1May 12, 2026
- 8-KCURRENT REPORTApr 9, 2026
- 10-KFORM 10-K FOR DEC 2025Apr 3, 2026
- 8-KFORM 8-KMar 9, 2026
- 8-KCURRENT REPORTFeb 20, 2026
- 8-KCURRENT REPORTFeb 5, 2026
- 8-KFORM 8-KDec 12, 2025
- 10-QFORM 10-Q FOR SEP 2025Nov 13, 2025
- DEF 14ADEFINITIVE PROXYOct 23, 2025
- 8-KCURRENT REPORTSep 30, 2025
- 10-QFORM 10-Q FOR JUN 2025Aug 12, 2025
- S-1FORM S-1Aug 5, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Two Sigma Investments | Q4 2025 | Q1 2026 | $1.63 | $1.16 | -29% |
| Citadel Advisors | Q3 2025 | open | $1.51 | $0.51 | -66% |
| Renaissance Technologies | Q3 2025 | Q1 2026 | $1.50 | $1.18 | -21% |
| Citadel Advisors | Q3 2024 | Q1 2026 | $0.00 | — | +0% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.